Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]

Unfortunately, I was not careful enough in checking the proof of the article and my address has some problems. I request you to add the amendment to the original article.

Thank you very much for your cooperation.